The global propylthiouracil (PTU) market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). PTU comes under thionamide drugs used in the treatment of hyperthyroidism which works by inhibiting the thyroid peroxidases (TPO), which catalyze the iodination of tyrosine residues in thyroglobulin and the oxidative coupling of iodinated tyrosines. The major factor expected to drive the market growth is the rising application of PTU in the treatment of Graves’ disease and hyperthyroidism (a condition where the thyroid gland produces too much thyroid hormone), including prior to surgery or radiotherapy. In addition, it is used as an adjunct in the treatment of thyrotoxicosis or thyroid storm since propylthiouracil inhibits peripheral conversion of thyroxine (T4) to triiodothyronine (T3).
Furthermore, a few studies also show that the paradoxically propylthiouracil has been shown to reverse histological changes of alcoholic hepatitis in rats and has been proposed as a possible treatment for this condition in men along with Twelve-day pretreatment with PTU prevented the Tylenol-induced increase in transaminase activities. An increase in hepatic reduced glutathione levels and prevention of inflammatory response to necrotic liver tissue appeared to be a mechanism for the protective action of hypothyroidism.
Another factor behind the growth of the global PTU market is that it remains the preferred antithyroid medication in the US. The major cause that PTU is more preferred in the US is that it is more highly protein-bound and crosses less efficiently into breast milk than methimazole (MMI). PTU is also considered preferable to use in women who breast-feed their infants. Some major players in the market include Apotex Inc., Teva Pharmaceutical Industries Ltd., and Hikma Pharmaceuticals plc, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Propylthiouracil (PTU) Market at: https://orionmarketreports.com/request-sample/?id=96540&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Apotex Inc., Teva Pharmaceutical Industries Ltd., and Hikma Pharmaceuticals plc, among others.
A full report Propylthiouracil (PTU) Market of is available at: https://orionmarketreports.com/propylthiouracil-ptu-market/96540/
Global Propylthiouracil (PTU) Market Report by Segment
By Type
- Finished Drug Product
- Active Pharmaceutical Ingredients
By Application
- Radioiodine Therapy
- Hyperthyroidism Operation
- Thyroid Medication
- Other
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
